Print Email Facebook Twitter Mouse models for atherosclerosis and pharmaceutical modifiers Title Mouse models for atherosclerosis and pharmaceutical modifiers Author Zadelaar, A.S.M. Kleemann, R. Verschuren, L. de Vries-van der Weij, J. van der Hoorn, J. Princen, H.M. Kooistra, T. TNO Kwaliteit van Leven Publication year 2007 Abstract Atherosclerosis is a multifactorial highly-complex disease with numerous etiologies that work synergistically to promote lesion development. The ability to develop preventive and ameliorative treatments will depend on animal models that mimic the human subject metabolically and pathophysiologically and will develop lesions comparable to those in humans. The mouse is the most useful, economic, and valid model for studying atherosclerosis and exploring effective therapeutic approaches. Among the most widely used mouse models for atherosclerosis are apolipoprotein E-deficient (ApoE) and LDL receptor-deficient (LDLr) mice. An up-and-coming model is the ApoE*3Leiden (E3L) transgenic mouse. Here, we review studies that have explored how and to what extent these mice respond to compounds directed at treatment of the risk factors hypercholesterolemia, hypertriglyceridemia, hypertension, and inflammation. An important outcome of this survey is that the different models used may differ markedly from one another in their response to a specific experimental manipulation. The choice of a model is therefore of critical importance and should take into account the risk factor to be studied and the working spectrum of the compounds tested. © 2007 American Heart Association, Inc. Subject BiologyBiomedical ResearchACE inhibitorsAT1 receptor antagonistsAtherosclerosisLXRMouse modelsPharmaceutical drugsPPARStatinsatorvastatinavasimibecandesartancaptoprilcholesterol acyltransferase inhibitordipeptidyl carboxypeptidase inhibitorhydralazinehydroxymethylglutaryl coenzyme A reductase inhibitorirbesartanlosartanly 465608n (2,2,2 trifluoroethyl) n [4 [2,2,2 trifluoro 1 hydroxy 1 (trifluoromethoxy)ethyl]phenyl]benzenesulfonamideolmesartanperindoprilperoxisome proliferator activated receptor alpha agonistpirinixic acidpitavastatinpravastatinquinaprilramiprilrosuvastatinsimvastatintelmisartantemocaprilunindexed drugvalsartanzofenoprilantihypertensive agentantilipemic agentapolipoprotein Eatherosclerosispathophysiologysensitivity and specificityAnimalsAntihypertensive AgentsAntilipemic AgentsApolipoproteins EAtherosclerosisDisease Models, AnimalDose-Response Relationship, DrugDrug Administration ScheduleDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypertensionMaleMiceMice, KnockoutMice, TransgenicSensitivity and Specificity To reference this document use: http://resolver.tudelft.nl/uuid:e7d344f4-137e-4a46-bd2d-86bd1ce859be DOI https://doi.org/10.1161/atvbaha.107.142570 TNO identifier 240117 ISSN 1079-5642 Source Arteriosclerosis, Thrombosis, and Vascular Biology, 27 (8), 1706-1721 Document type article Files To receive the publication files, please send an e-mail request to TNO Library.